152 related articles for article (PubMed ID: 10886102)
1. Inherited renal cancer.
Turner KJ
BJU Int; 2000 Jul; 86(2):155-64;quiz i. PubMed ID: 10886102
[No Abstract] [Full Text] [Related]
2. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
3. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.
Shuin T; Kondo K; Ashida S; Okuda H; Yoshida M; Kanno H; Yao M
Contrib Nephrol; 1999; 128():1-10. PubMed ID: 10597373
[No Abstract] [Full Text] [Related]
4. Genetics of renal tumours.
Fleming S
Cancer Metastasis Rev; 1997 Jun; 16(1-2):127-40. PubMed ID: 9156283
[TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau disease: the role of gene analysis in affected families.
Riegler P; Huber W; Corradini R; Neumann HP; Glaesker S; Sessa A
Nephron; 2000 Jan; 84(1):95-7. PubMed ID: 10644921
[No Abstract] [Full Text] [Related]
6. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of endothelial cells derived from von Hippel-Lindau-related renal cancer.
Los M; Kerckhaert OA; Zewald R; van Amstel HK; Voest EE
J Natl Cancer Inst; 2000 Oct; 92(20):1688-9. PubMed ID: 11036115
[No Abstract] [Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.
Gnarra JR; Duan DR; Weng Y; Humphrey JS; Chen DY; Lee S; Pause A; Dudley CF; Latif F; Kuzmin I; Schmidt L; Duh FM; Stackhouse T; Chen F; Kishida T; Wei MH; Lerman MI; Zbar B; Klausner RD; Linehan WM
Biochim Biophys Acta; 1996 Mar; 1242(3):201-10. PubMed ID: 8603073
[No Abstract] [Full Text] [Related]
10. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
11. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
Wiesener MS; Eckardt KU
Nephrol Dial Transplant; 2002 Mar; 17(3):356-9. PubMed ID: 11865075
[No Abstract] [Full Text] [Related]
13. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
Decker HJ; Weidt EJ; Brieger J
Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
[TBL] [Abstract][Full Text] [Related]
15. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
[TBL] [Abstract][Full Text] [Related]
16. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
17. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
18. [Current progress in the diagnosis and treatment of renal cell carcinoma].
Tsukamoto T; Takahashi A; Kitamura H
Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):779-85. PubMed ID: 12607966
[No Abstract] [Full Text] [Related]
19. Third International Meeting on von Hippel-Lindau disease.
Zbar B; Kaelin W; Maher E; Richard S
Cancer Res; 1999 May; 59(9):2251-3. PubMed ID: 10232616
[TBL] [Abstract][Full Text] [Related]
20. The kidney and von Hippel-Lindau disease: impact of molecular genetic analysis of the VHL gene for clinical management.
Neumann HP; Bender BU; Schultze-Seemann W; Krause T; Altehoefer C; Scheremet R; Orszagh M; Schwarzkopf G; Januszewicz A; Janetschek G; Riegler P
Contrib Nephrol; 1997; 122():102-8. PubMed ID: 9399049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
